Phathom Pharmaceuticals (PHAT) Equity Average (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Equity Average of -$387.6 million for Q1 2026, down 30.94% year-over-year from -$561.2 million in Q1 2025, and up 9.94% quarter-over-quarter from -$430.4 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Equity Average (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Equity Average data on file, last reported at -$387.6 million in Q1 2026.
- Equity Average for Q1 2026 came in at -$387.6 million, down 30.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$387.6 million (down 30.94% YoY), and the FY2025 annual result was -$345.9 million, down 111.97% from the prior year.
- Equity Average rose to -$387.6 million in Q1 2026 per PHAT's latest filing, from -$430.4 million in the prior quarter.
- Over five years, Equity Average peaked at $55.1 million in Q1 2022 and troughed at -$430.4 million in Q4 2025.
- A 5-year average of -$164.3 million and a median of -$110.6 million in 2024 frame the typical range for Equity Average.
- The sharpest annual moves came in 2023 and 2024: Equity Average soared 99.48% in 2023, then tumbled 243218.5% in 2024.
- A 5-year view of Equity Average shows it stood at -$50.6 million in 2022, then advanced by 10.57% to -$45.3 million in 2023, then plunged by 386.78% to -$220.3 million in 2024, then plunged by 95.31% to -$430.4 million in 2025, then advanced by 9.94% to -$387.6 million in 2026.
- Business Quant data shows PHAT's Equity Average at -$387.6 million in Q1 2026, -$430.4 million in Q4 2025, and -$414.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -387.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -387.56 Mn |
| Dec 31, 2025 | -430.35 Mn |
| Sep 30, 2025 | -414.18 Mn |
| Jun 30, 2025 | -372.11 Mn |
| Mar 31, 2025 | -295.98 Mn |
| Dec 31, 2024 | -220.35 Mn |
| Sep 30, 2024 | -210.47 Mn |
| Jun 30, 2024 | -191.17 Mn |
| Mar 31, 2024 | -110.63 Mn |
| Dec 31, 2023 | -45.27 Mn |
| Sep 30, 2023 | -86,500.00 |
| Jun 30, 2023 | -36.30 Mn |
| Mar 31, 2023 | -82.50 Mn |
| Dec 31, 2022 | -50.62 Mn |
| Sep 30, 2022 | -16.71 Mn |
| Jun 30, 2022 | 15.52 Mn |
| Mar 31, 2022 | 55.10 Mn |
| Dec 31, 2021 | 87.82 Mn |
| Sep 30, 2021 | 117.80 Mn |
| Jun 30, 2021 | 148.23 Mn |